Increased phosphorylation of 4E‑binding protein 1 predicts poor prognosis for patients with colorectal cancer

Miao,Yufeng; Chen,Lige; Shi,Cuifen; Fan,Rengen; Chen,Ping; Liu,Hongqi; Xia,Aihua; Qian,Haixin

doi:10.3892/mmr.2017.6352

Increased phosphorylation of 4E‑binding protein 1 predicts poor prognosis for patients with colorectal cancer

Authors:
- Yufeng Miao
- Lige Chen
- Cuifen Shi
- Rengen Fan
- Ping Chen
- Hongqi Liu
- Aihua Xia
- Haixin Qian
View Affiliations

Affiliations: Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China, Department of Pharmacy, Yancheng First People's Hospital, Yancheng, Jiangsu 224001, P.R. China, Department of Hepatology, Yancheng No. 2 People's Hospital, Yancheng, Jiangsu 224002, P.R. China, Department of General Surgery, Yancheng First People's Hospital, Yancheng, Jiangsu 224001, P.R. China, Department of Medical Oncology, Yancheng First People's Hospital, Yancheng, Jiangsu 224001, P.R. China, Department of Clinical Laboratory, Yancheng First People's Hospital, Yancheng, Jiangsu 224001, P.R. China
Published online on: March 22, 2017 https://doi.org/10.3892/mmr.2017.6352
Pages: 3099-3104

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

As demonstrated in previous studies, the phosphorylated form of 4E‑binding protein 1 (p‑4E‑BP1) may be a suitable tumor biomarker. The aim of the current study was to examine the expression status of p‑4E‑BP1 in colorectal cancer (CRC), in order to determine its clinical significance. The present study enrolled 89 patients with CRC that had undergone radical resection. Paired tumor and adjacent normal tissues were evaluated using immunohistochemistry to detect the protein expression of p‑4E‑BP1 and phosphatase and tensin homolog (PTEN). The study identified 53 cases (59.6%) that exhibited moderate or high expression of p‑4E‑BP1 in tumor tissues, compared with little or no expression in the adjacent normal tissues. Conversely, PTEN protein expression was markedly lower in CRC compared with adjacent normal tissues. p‑4E‑BP1 protein upregulation tissues samples was consistent with PTEN downregulation in CRC samples. p‑4E‑BP1 overexpression was predominant in patients with metastasis to the regional lymph nodes. Moderate/high expression of p‑4E‑BP1 protein was significantly associated with adverse overall survival (OS) in patients. Statistical analysis using the Cox proportional hazards model, indicated that p‑4E‑BP1 expression was an independent factor suitable for predicting OS in CRC patients, which was independent of lymph node metastasis. In conclusion, p‑4E‑BP1 protein expression appears to be upregulated in CRC, suggesting that it may be a suitable biomarker for predicting CRC prognosis.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Saif MW and Chu E: Biology of colorectal cancer. Cancer J. 16:196–201. 2010. View Article : Google Scholar : PubMed/NCBI
3	Armengol G, Rojo F, Castellvi J, Iglesias C, Cuatrecasas M, Pons B, Baselga J and Cajal Ramón y S: 4E-binding protein 1: A key molecular ‘funnel factor’ in human cancer with clinical implications. Cancer Res. 67:7551–7555. 2007. View Article : Google Scholar : PubMed/NCBI
4	Magagnin MG, van den Beucken T, Sergeant K, Lambin P, Koritzinsky M, Devreese B and Wouters BG: The mTOR target 4E-BP1 contributes to differential protein expression during normoxia and hypoxia through changes in mRNA translation efficiency. Proteomics. 8:1019–1028. 2008. View Article : Google Scholar : PubMed/NCBI
5	Barnhart BC, Lam JC, Young RM, Houghton PJ, Keith B and Simon MC: Effects of 4E-BP1 expression on hypoxic cell cycle inhibition and tumor cell proliferation and survival. Cancer Biol Ther. 7:1441–1449. 2008. View Article : Google Scholar : PubMed/NCBI
6	Rojo F, Najera L, Lirola J, Jiménez J, Guzmán M, Sabadell MD, Baselga J and Cajal Ramon y S: 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res. 13:81–89. 2007. View Article : Google Scholar : PubMed/NCBI
7	Castellvi J, Garcia A, Rojo F, Ruiz-Marcellan C, Gil A, Baselga J and Cajal Ramon y S: Phosphorylated 4E binding protein 1: A hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer. 107:1801–1811. 2006. View Article : Google Scholar : PubMed/NCBI
8	Benavente S, Vergés R, Hermosilla E, Fumanal V, Casanova N, García A, Ramón Y, Cajal S and Giralt J: Overexpression of phosphorylated 4E-BP1 predicts for tumor recurrence and reduced survival in cervical carcinoma treated with postoperative radiotherapy. Int J Radiat Oncol Biol Phys. 75:1316–1322. 2009. View Article : Google Scholar : PubMed/NCBI
9	Castellvi J, Garcia A, Ruiz-Marcellan C, Hernández-Losa J, Peg V, Salcedo M, Gil-Moreno A and Cajal Ramon y S: Cell signaling in endometrial carcinoma: Phosphorylated 4E-binding protein-1 expression in endometrial cancer correlates with aggressive tumors and prognosis. Hum Pathol. 40:1418–1426. 2009. View Article : Google Scholar : PubMed/NCBI
10	Yeh CJ, Chuang WY, Chao YK, Liu YH, Chang YS, Kuo SY, Tseng CK, Chang HK and Hsueh C: High expression of phosphorylated 4E-binding protein 1 is an adverse prognostic factor in esophageal squamous cell carcinoma. Virchows Arch. 458:171–178. 2011. View Article : Google Scholar : PubMed/NCBI
11	Jiao X, Pan J, Qian J, Luo T, Wang Z, Yu G and Wang J: Overexpression of p-4ebp1 in Chinese gastric cancer patients and its correlation with prognosis. Hepatogastroenterology. 60:921–926. 2013.PubMed/NCBI
12	Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC cancer staging manual. 7th. New York: Springer; 2010
13	Ueno H, Kajiwara Y, Shimazaki H, Shinto E, Hashiguchi Y, Nakanishi K, Maekawa K, Katsurada Y, Nakamura T, Mochizuki H, et al: New criteria for histologic grading of colorectal cancer. Am J Surg Pathol. 36:193–201. 2012. View Article : Google Scholar : PubMed/NCBI
14	Rousseau B, Chibaudel B, Bachet JB, Larsen AK, Tournigand C, Louvet C, André T and de Gramont A: GERCOR (French Oncology Research Group): Stage II and stage III colon cancer: Treatment advances and future directions. Cancer J. 16:202–209. 2010. View Article : Google Scholar : PubMed/NCBI
15	De Sousa E, Melo F, Vermeulen L, Fessler E and Medema JP: Cancer heterogeneity-a multifaceted view. EMBO Rep. 14:686–695. 2013. View Article : Google Scholar : PubMed/NCBI
16	Walker AS, Johnson EK, Maykel JA, Stojadinovic A, Nissan A, Brucher B, Champagne BJ and Steele SR: Future directions for the early detection of colorectal cancer recurrence. J Cancer. 5:272–280. 2014. View Article : Google Scholar : PubMed/NCBI
17	Sinicrope FA and Sargent DJ: Molecular pathways: Microsatellite instability in colorectal cancer: Prognostic, predictive, and therapeutic implications. Clin Cancer Res. 18:1506–1512. 2012. View Article : Google Scholar : PubMed/NCBI
18	Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, et al: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60–00 trial. J Clin Oncol. 28:466–474. 2010. View Article : Google Scholar : PubMed/NCBI
19	Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, Yamada H, Hayama T, Inoue E, Tamura J, et al: Chromosomal instability (CIN) phenotype, CIN high or CIN low, predicts survival for colorectal cancer. J Clin Oncol. 30:2256–2264. 2012. View Article : Google Scholar : PubMed/NCBI
20	O'Connell MJ, Lavery I, Yothers G, Paik S, Clark-Langone KM, Lopatin M, Watson D, Baehner FL, Shak S, Baker J, et al: Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol. 28:3937–3944. 2010. View Article : Google Scholar : PubMed/NCBI
21	Heesom KJ, Gampel A, Mellor H and Denton RM: Cell cycle-dependent phosphorylation of the translational repressor eIF-4E binding protein-1 (4E-BP1). Curr Biol. 11:1374–1379. 2001. View Article : Google Scholar : PubMed/NCBI
22	Topisirovic I, Ruiz-Gutierrez M and Borden KL: Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities. Cancer Res. 64:8639–8642. 2004. View Article : Google Scholar : PubMed/NCBI
23	Halilovic E, She QB, Ye Q, Pagliarini R, Sellers WR, Solit DB and Rosen N: PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Res. 70:6804–6814. 2010. View Article : Google Scholar : PubMed/NCBI
24	Averous J and Proud CG: When translation meets transforma-tion: The mTOR story. Oncogene. 25:6423–6435. 2006. View Article : Google Scholar : PubMed/NCBI
25	Petricoin EF III, Espina V, Araujo RP, Midura B, Yeung C, Wan X, Eichler GS, Johann DJ Jr, Qualman S, Tsokos M, et al: Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res. 67:3431–3440. 2007. View Article : Google Scholar : PubMed/NCBI
26	O'Reilly KE, Warycha M, Davies MA, Rodrik V, Zhou XK, Yee H, Polsky D, Pavlick AC, Rosen N, Bhardwaj N, et al: Phosphorylated 4E-BP1 is associated with poor survival in melanoma. Clin Cancer Res. 15:2872–2878. 2009. View Article : Google Scholar : PubMed/NCBI
27	Avdulov S, Li S, Michalek V, Burrichter D, Peterson M, Perlman DM, Manivel JC, Sonenberg N, Yee D, Bitterman PB and Polunovsky VA: Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell. 5:553–563. 2004. View Article : Google Scholar : PubMed/NCBI
28	Diab-Assaf M, Abou-Khouzam R, Saadallah-Zeidan N, Habib K, Bitar N, Karam W, Liagre B, Harakeh S and Azar R: Expression of eukaryotic initiation factor 4E and 4E binding protein 1 in colorectal carcinogenesis. Int J Clin Exp Pathol. 8:404–413. 2015.PubMed/NCBI
29	Simi L, Pratesi N, Vignoli M, Sestini R, Cianchi F, Valanzano R, Nobili S, Mini E, Pazzagli M and Orlando C: High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol. 130:247–253. 2008. View Article : Google Scholar : PubMed/NCBI
30	She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T, Solit DB and Rosen N: 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell. 18:39–51. 2010. View Article : Google Scholar : PubMed/NCBI
31	Hsieh AC, Costa M, Zollo O, Davis C, Feldman ME, Testa JR, Meyuhas O, Shokat KM and Ruggero D: Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell. 17:249–261. 2010. View Article : Google Scholar : PubMed/NCBI
32	Weng LP, Smith WM, Brown JL and Eng C: PTEN inhibits insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer model. Hum Mol Genet. 10:605–616. 2001. View Article : Google Scholar : PubMed/NCBI